Sigma-Aldrich Hopes Benitec s RNAi IP Will Bolster Play, Calm Pharma s Litigation Fears | GenomeWeb

Control over intellectual property and protection against potential patent litigation are the key reasons behind Sigma-Aldrich's decision this week to license Benitec's RNAi patent portfolio and buy a stake in the company, according to a Sigma-Aldrich executive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.